Bas Groot Koerkamp

HPB-transplant surgeon

[Arndt Vogel @ArndtVogel]

Adjuvant hepatic arterial infusion pump CTx with floxuridine for resectable CRC metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial.
#ASCO26
👉mPFS 15 vs 15.5 mo
👉similar 5-yr OS rate
🧐no benefit for HAIP...
@myesmo @ASCO

[Grainne O'Kane @graokane]

Adjuvant HAIP resectable #CRCLM with low CRS #ASCO26
➡️n=110 resection+pump v 108pts resection alone
❎no ⬆️in mPFS 15.0 v 16.0 mths
➡️hepatic PFS 37.6 v 21.8mths
90 day postop mortality 4pts v 1pt
No role in this setting but feasible @ASCO @OncoAlert
Imp study & 👏🏻presentation

[Syed A. Ahmad @SyedAAhmad5]

Take a listen. 👇🏼👇🏼

[Journal of Clinical Oncology @JCO_ASCO]

Postoperative Hepatic Arterial Infusion with Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial. Co-authored by @GelliMaximilia1.

Read the full article. https://t.co/jJ1BOCaAsP

[NEJM @NEJM]

Original Article: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer https://t.co/9y7xLrCuYV

Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer https://t.co/mz3fgnCNUi

#Oncology #Gastroenterology

[JAMA @JAMA_current]

📊 Research Summary: Among patients with multiorgan metastatic #ColorectalCancer, tumor debulking combined with systemic chemotherapy failed to provide a survival benefit over chemotherapy alone and resulted in higher rates of serious adverse events.

https://t.co/y8oM7HVND5

[Ferran Fece de la Cruz @FerranFeceCruz]

Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma @Cancer_Cell @curecc @KRASKickers #KRAS
https://t.co/9m8SqLQhZk

[Pashtoon Kasi MD, MS @pashtoonkasi]

#AACR26☝🏽A question that’s lingered for years:

dMMR/MSI-H➡️immunotherapy… but can we induce it?

Can pMMR/MSS tumors be converted➡️dMMR/MSI-H—and made responsive to IO?

Remarkably, this team has done it.✅ 🤯

🎯 NP1867 🔆🔅

@CD_AACR @OncoAlert @AACR

https://t.co/KDuoURe6q3

[Adriana Zucchiatti @zucchiatti_]

Cholangiocarcinoma 2026: status quo, unmet needs and priorities
https://t.co/k8ZYUVKHAI
#liverpath

[Allen Braden @allen_explains]

This 2-hour Stanford lecture breaks down how models like ChatGPT and Claude are actually built, clearer than what many people in top AI roles ever get exposed to.

Save this and set aside two hours today. It might end up being the most valuable thing you learn all week.

[Anirban Maitra @Aiims1742]

🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!

AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O

[Wungki Park, MD MS @CentralParkWMD]

New drugs take aim at one of cancer’s deadliest mutations

“You can actually re-educate the cell: ‘hey, this is disposable, just remove it’”

https://t.co/6lXYFONqxz

[Giovanni Marchegiani @Gio_Marchegiani]

IPMN 🫧 and adjuvant chemotherapy: current evidence

🍇 1.3k InvasiveIPMN / 60% had adjuvant chemo
💉 70% had contemporary regimens
😢 NO survival benefit (median 70 months)

👉 Controlled data on specific IPMN type urgently needed! 🧐 @JAMANetworkOpen

https://t.co/H5Kurx2nOS

[Flavio G Rocha, MD, FACS, FSSO @FlavioRochaMD]

What is future for #PDAC❓PAXG, KRAS, FFX
@OHSUKnight @PanCAN @SocSurgOnc

[Julie Hallet @HalletJulie]

Prismatic loupes use deflected optics to get better magnified view of the field while keeping a neutral head/neck posture 👉🏻 ⬇️ flexion, ⬇️ strain, ⬆️ ergonomics vs traditional loupes 🙌
Tried them at #SSO2026 & can’t wait to get my pair and report back on the experience 👀

[Alessandro Vitale @Vaital73]

TRANSPLANT BENEFIT IN CRLM: OUR PAPER, NOW WITH EDITORIAL INSIGHT

Honoured to see our paper in Liver Transplantation, accompanied by an editorial emphasising its importance and practical implications [1].
Our study [2] provides the first real-world external validation of the TransMet trial criteria for unresectable colorectal liver metastases, demonstrating that the survival benefit observed in the trial is reproducible outside the trial setting and quantifying the transplant advantage in a clinically meaningful manner.
The editorial emphasises several key points raised by our work: the importance of external validation, the need for refined biological selection, the implications for allocation policy, and the significance of multidisciplinary referral and decision-making in this evolving field.
I am grateful to all co-authors and collaborators for their valuable contributions to this significant step forward in transplant oncology.

[1]https://t.co/uRPK9s5vkF
[2]https://t.co/RU8DjxfPSy

#LiverTransplantation #TransplantOncology #CRLM #TransMet #LiverTransplant #ColorectalLiverMetastases #SurgicalOncology #Research

[NEJM @NEJM]

Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. Full phase 2–3 ZSAB-neoGOLP trial results and Research Summary: https://t.co/PpNO71uhur

[Lee M. Ocuin MD, FACS @TheNotoriousHPB]

We can keep doing prevention trials or simply accept that mitigation is the strategy. Too complex of an anastomosis with too many variables that we cannot control, including interuser variability in technical skill. Antibiotics mitigate carte blanche.

https://t.co/YwTnW6Bs2y

[Eric Topol @EricTopol]

🆕 @ScienceMagazine
An exciting new approach vs pancreatic cancer: "cancer interception"
Considered ubiquitous, the pancreas in healthy adults has hundreds of PanINs of microscopic premalignant cancer that can be regressed in the experimental model
https://t.co/erVtthSMjS
https://t.co/2xHIYdIPrx

[Anirban Maitra @Aiims1742]

Could it be this easy? I am not sure to be honest - although it would be nice!
Anyone running this trial?

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in #PancreaticCancer
https://t.co/Gt75BwW18c